KR20010089858A - Development of fermented dairy products containing CLA - Google Patents
Development of fermented dairy products containing CLA Download PDFInfo
- Publication number
- KR20010089858A KR20010089858A KR1020000014858A KR20000014858A KR20010089858A KR 20010089858 A KR20010089858 A KR 20010089858A KR 1020000014858 A KR1020000014858 A KR 1020000014858A KR 20000014858 A KR20000014858 A KR 20000014858A KR 20010089858 A KR20010089858 A KR 20010089858A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented milk
- cla
- lactic acid
- acid bacteria
- weight
- Prior art date
Links
- 235000021001 fermented dairy product Nutrition 0.000 title 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 241000894006 Bacteria Species 0.000 claims abstract description 27
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 25
- 239000004310 lactic acid Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 15
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 12
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 12
- 239000002285 corn oil Substances 0.000 claims abstract description 4
- 235000005687 corn oil Nutrition 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 235000015140 cultured milk Nutrition 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 235000020238 sunflower seed Nutrition 0.000 claims description 6
- 241000030538 Thecla Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 10
- 235000014048 cultured milk product Nutrition 0.000 abstract description 8
- 239000003674 animal food additive Substances 0.000 abstract description 4
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 235000019486 Sunflower oil Nutrition 0.000 abstract 1
- 239000002600 sunflower oil Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 229940017800 lactobacillus casei Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019629 palatability Nutrition 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 2
- IOCYQQQCJYMWDT-UHFFFAOYSA-N (3-ethyl-2-methoxyquinolin-6-yl)-(4-methoxycyclohexyl)methanone Chemical compound C=1C=C2N=C(OC)C(CC)=CC2=CC=1C(=O)C1CCC(OC)CC1 IOCYQQQCJYMWDT-UHFFFAOYSA-N 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010007269 Carcinogenicity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 231100000260 carcinogenicity Toxicity 0.000 description 2
- 230000007670 carcinogenicity Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019614 sour taste Nutrition 0.000 description 2
- GKJZMAHZJGSBKD-UHFFFAOYSA-N (10E,12E)-Octadeca-9,11-dienoic acid Natural products CCCCCC=CC=CCCCCCCCCC(O)=O GKJZMAHZJGSBKD-UHFFFAOYSA-N 0.000 description 1
- GKJZMAHZJGSBKD-BLHCBFLLSA-N (10e,12e)-octadeca-10,12-dienoic acid Chemical compound CCCCC\C=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-BLHCBFLLSA-N 0.000 description 1
- GKJZMAHZJGSBKD-ANYPYVPJSA-N 10-trans-12-cis-linoleic acid Natural products CCCCCC=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-ANYPYVPJSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 244000126745 Lactobacillus acidophilus 30SC Species 0.000 description 1
- 235000014111 Lactobacillus acidophilus 30SC Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 235000010727 Lactobacillus helveticus DSM 20075 Nutrition 0.000 description 1
- 241001616644 Lactobacillus helveticus DSM 20075 = CGMCC 1.1877 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001603151 Philus Species 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 씨엘에이(CLA : Conjugated Linoleic Acid, 공액리놀레인산)를 함유하는 발효유 조성물 및 그 제조방법에 관한 것으로서, 보다 상세하게는 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성과 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용될 수 있는 CLA를 함유하는 발효유 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a fermented milk composition containing CLA (Conjugated Linoleic Acid, conjugated linoleic acid) and a method of manufacturing the same, and more specifically, the anticancer effect of fermented milk and the anticancer effect of CLA interact more organically. The present invention relates to a fermented milk composition containing CLA which can be suitably used for the production of improved functionalities and suits, feed additives and powdered lactic acid bacteria products, and a method for producing the same.
최근에 이르러 현대인의 소득수준이 향상됨에 따라서 고 단백질, 고 콜레스테롤의 음식을 많이 접하게 되었고, 이로 인하여 각종 성인성 질환이 급증하였으며, 그 중 암과 동맥경화 등이 현대인의 사망요인으로 매우 중요하게 인식되어 왔다. 이들 질환과 관련하여 유산균 및 발효유 제품에 대한 여러 가지 연구가 개시되었으며, 그 결과 인체에 유용한 다양한 유산균이 개발되었고, 이러한 유산균을 함유한 발효유 제품이 다양하게 상품화되고 있다.In recent years, as the income level of modern people has improved, a lot of foods of high protein and high cholesterol have been encountered, and as a result, various adult diseases have increased rapidly. Among them, cancer and arteriosclerosis are considered as important death factors of modern people. Has been. In connection with these diseases, various studies on lactic acid bacteria and fermented milk products have been disclosed. As a result, various lactic acid bacteria useful for the human body have been developed, and various fermented milk products containing such lactic acid bacteria have been commercialized.
유산균 발효유 제품은 우유와 함께 우리 나라는 물론 외국의 대다수 나라에서 일상 섭취하는 주요한 식품으로 일상의 생활에 자리를 잡아가고 있다.Lactobacillus fermented milk products, along with milk, are the main foods consumed in our country as well as in most foreign countries.
초기 유산균 발효유 제품의 유래는 정확하지는 않으나, 생산자가 향미(香味)성 요인을 모르는 상태에서 저장성을 높이기 위해 발효식품을 제조한 것으로 보여지고 있고, 최근에 이르러서는 발효과정의 조정 및 인체에 유용한 물질 함유를 통하여 제품의 질이 향상된 발효유 제품이 다양하게 선보이고 있다.Although the origin of early lactic acid bacteria fermented milk products is not accurate, it has been shown that producers manufactured fermented foods to increase shelf life without knowing flavor factors, and recently, substances useful for the adjustment of fermentation process and human body Fermented milk products have been introduced in a variety of ways to improve the quality of their products.
이러한 발효유 제품이 영양생리학적으로 우수한 식품으로 자리를 잡아가고 있는 것은 정기적인 체내 흡수 시에는 장수 및 건강에 좋다고 알려져 있기 때문으로 사료된다.This fermented milk product is becoming a nutritionally physiologically superior food because it is known to be good for longevity and health when absorbed regularly in the body.
유산균 제품에 의한 건강증진 효과는 유산균의 배양을 통하여 형성된 대사산물이 장내 부패균의 성장을 억제함에 기인하는 것으로 알려져 있고, 이러한 인체에 유용한 유산균을 함유하는 발효유는 제품의 보관성면에서 볼 때, 우유에 비하여 품질보존이 용이한 점, 소화흡수성이 높은 점, 지방의 부분적인 분리에 의한 지방산 유리효과가 높은 점, 장내의 병원성 균의 감염을 저지할 수 있다는 점, 장내의 유해균의 증식을 억제하여 항암효과를 직, 간접적으로 얻을 수 있다는 점, 혈중의 콜레스테롤의 저하작용이 있다는 점 외에도 변비와 설사 억제, 유해균에 대한 면역체계를 증진시킨다는 점등의 여러 가지 인체에 건강증진 효과를 가지고 있기 때문에 다양하게 상품화되고 있는 것이 현 실정이다.The health-promoting effect of lactic acid bacteria products is known to be due to the inhibition of the growth of intestinal rot by the metabolites formed through the culture of lactic acid bacteria. Fermented milk containing lactic acid bacteria useful for the human body is found in milk, in terms of storage properties of the product. Compared with its easy-to-preserve quality, high digestive absorption, high fatty acid free effect by partial separation of fat, it can prevent infection of pathogenic bacteria in the intestine, and anti-cancer by inhibiting the growth of harmful bacteria in the intestine. In addition to its direct and indirect effects, and its lowering of cholesterol in the blood, it has a variety of products that promote health in the human body, which helps to suppress constipation and diarrhea and enhances the immune system against harmful bacteria. It is the present situation that is becoming.
이러한 산업적 이용가치가 있는 유산균은 최근까지 끊임없는 개량을 통하여 선발되고 있는데, 이러한 유용 균주들이 인체나 동물에게 유익하게 작용하려면 장내에 정상적으로 존재하는 균주이어야 하고, 소화기관을 통과하면서 생존해야 하며, 장내에서 정착이 가능한 균주이어야만 상기에서 언급한 여러 가지 건장증진효과가 보장이 될 것이다.Lactobacillus with industrial value has been selected through continuous improvement until recently. In order for these useful strains to benefit humans or animals, they must be normally present in the intestine, survive through the digestive system, and enter the intestine. Only if the strain can be settled in the various health promotion effects mentioned above will be guaranteed.
한편, 씨엘에이(CLA)란 cis 혹은 trans 배열에 공액화 2중결합 (conjugated double bonds)을 가지고 있는 리놀레인산의 위치적 및 형태적 이성체(positional and geometric isomers)를 일컫는 일반적인 명칭이다. 이들 CLA는 9, 11위치 및 10, 12위치에 cis 혹은trans 배열을 하기도 하며, 이론적으로는 리놀레인산(cis-9, cis-12 octadecadienoic acid)의 이성화반응에 의하여 8개의 9, 11 옥타데카디에노인산(octadecadienoic acid) 및 10, 12 옥타디카디에노인산(cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-10, trans-12; trans-10, cis-12 및 trans-10, trans-12)이 형성될 수가 있다.On the other hand, CLA is a generic name for the positional and geometric isomers of linoleic acid having conjugated double bonds in the cis or trans configuration. These CLAs also have cis or trans arrangements at positions 9, 11 and 10, 12, and theoretically, 8 9, 11 octadecas by isomerization of linoleic acid (cis-9, cis-12 octadecadienoic acid). Octadecadienoic acid and 10, 12 octadecadienoic acid (cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis -10, cis-12; cis-10, trans-12; trans-10, cis-12 and trans-10, trans-12) can be formed.
그러나, 자연적으로 여러 가지 식품에 존재하는 CLA, 특별히 반추동물 유래의 유제품 및 육류에 천연적으로 함유되어 있으며, 발견되는 총 CLA중 cis-9, trans-11 옥타데카디에노인산이 85∼95%를 차지하고 있다(TransFatty Acids in Human Nutrition : edited by J. L Sebedio and W.W Christie. 1998.Chapter 9. 261∼302page. The Oilypress Ltd).However, CLA, especially ruminant-derived dairy products and meats, which are naturally present in many foods, contains 85-95% of cis-9 and trans-11 octadecadienoic acid. (TransFatty Acids in Human Nutrition: edited by J. L Sebedio and WW Christie. 1998. Chapter 9. 261 to 302. The Oilypress Ltd).
이러한 씨엘에이(CLA)는 높은 항동맥경화를 지님과 동시에(Lee, K. N. 등 1994, Atherosclerosis 108:19) 특히, 동물실험에서 발암물질에의 노출로 인한 대장암, 위암, 유방암 및 피부암 유발을 억제하는 작용을 가진 것으로 보고 되었다(Ha, Y. L. 등 1990, Cancer Res. 50:1097; Belury, M. A. 등 1996, Nutr. Cancer 26:149; Ip, C. 등 1991, Cancer Res. 50:6118; Liew, C. 등 1996, Carcinogenesis 16:3037).While these CLAs have high anti-arteriosclerosis (Lee, KN et al. 1994, Atherosclerosis 108: 19), they inhibit the induction of colorectal, gastric, breast and skin cancers due to exposure to carcinogens in animal experiments. (Ha, YL et al. 1990, Cancer Res. 50: 1097; Belury, MA et al. 1996, Nutr. Cancer 26: 149; Ip, C. et al. 1991, Cancer Res. 50: 6118; Liew, C. et al. 1996, Carcinogenesis 16: 3037).
CLA 함량을 식품에서 분석하는 방법으로는 가스크로마토그래피 (Gas Chromatography)를 주로 이용하는데, 추출하는 조건 및 분석하는 방법에 따라서 다소 차이가 있다.As a method of analyzing CLA content in food, gas chromatography (Gas Chromatography) is mainly used, but there are differences depending on the extraction conditions and the method of analysis.
본 발명자는 씨엘에이(CLA) 생성에 관여하는 요인을 분석하여 그 함량을 증가시키는 연구를 수행한 결과 새로운 씨엘에이(CLA) 분석방법을 정립할 수 있었다(동일 출원인에 의한 미합중국 Journal of Food Science 학회지 64권 5호 792쪽).As a result of analyzing the factors involved in the production of CLA and increasing its content, the inventors were able to establish a new method for analyzing CLA (the Journal of the US Journal of Food Science by the same applicant) 64, no. 5, p. 792).
이러한 방법을 이용하면 보다 효과적으로 씨엘에이(CLA) 함량을 측정 할 수 있을 것이다.Using this method will be able to measure the CLA content more effectively.
또한, 낙농제품 중에는 천연적으로 씨엘에이(CLA)를 미량함유하고 있으나 (Chin, S. F. 등 1992, J. Food Comp. Anal. 5:185) 항암효과를 보이는 수준에는 미치지 못하기 때문에 씨엘에이(CLA) 함량을 제품 내에서 증가시키는 것이 요구된다. 동물 실험 결과 씨엘에이(CLA) 섭취량이 식품 중 0.1% 이상인 경우에 효과적으로 발암을 억제하는 것으로 나타났으며, 이는 낙농식품을 주식으로 하는 미국인 평균 씨엘에이(CLA) 섭취량의 3배에 해당하는 수치이다(Ip, C. 등 1994, Cancer Res. 54:1212).In addition, dairy products naturally contain trace amounts of CLA (Chin, SF et al. 1992, J. Food Comp. Anal. 5: 185). ) Increasing the content in the product. Animal studies have shown that CLA intake is more than 0.1% of food, effectively inhibiting carcinogenesis, which is three times the average CLA intake of dairy foods as a staple. (Ip, C. et al. 1994, Cancer Res. 54: 1212).
이러한 씨엘에이(CLA)를 낙농식품 중에 다량 함유하게 하는 방법으로는 정제된 씨엘에이(CLA), 또는 씨엘에이(CLA)를 많이 함유하고 있는 지방질의 인위적 첨가 등이 있으나 제조 과정 중에 첨가하게 되면 제조공정상 소실될 우려가 있으며 가격이 높아지게 되는 단점이 있다.The method of containing a large amount of CLA in dairy foods includes artificial addition of purified CLA or CLA, but if it is added during the manufacturing process, There is a risk of normal loss and the price increases.
따라서, 본 발명은 상기의 문제점을 해결하기 위한 것으로서,Therefore, the present invention is to solve the above problems,
본 발명의 목적은 씨엘에이(CLA)를 생성하는 유산균을 선발하여 그 유산균을 발효유 제조에 이용함으로서, 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성이 보장되고, 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용함에 있다.An object of the present invention is to select the lactic acid bacteria that produce the CLA (CLA) by using the lactic acid bacteria in the production of fermented milk, the anti-cancer effect of fermented milk and the anticancer effect of CLA organically interact with each other to ensure improved functionality, Appropriate use in the manufacture of feed additives and powdered lactic acid bacteria products.
본 발명의 상기 목적은 유산균을 이용하여 발효유 내의 유효성분으로서 CLA를 0.001~5 중량부를 함유하는 발효유 조성물과 이러한 발효유 조성물을 제조하는 방법으로서 유산균을 이용하여 발효유 내의 유효성분으로서 CLA를 0.001~5 중량부를 첨가하는 제조방법에 의하여 달성된다.The above object of the present invention is a fermented milk composition containing 0.001 to 5 parts by weight of CLA as an active ingredient in fermented milk using lactic acid bacteria and 0.001 to 5 parts by weight of CLA as an active ingredient in fermented milk using lactic acid bacteria as a method for producing such fermented milk composition. It is achieved by the manufacturing method of adding a part.
이하, 본 발명은 하기의 실시 예에 의해 보다 구체적으로 설명될 것이나, 이러한 실시 예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail by the following examples, but is not limited to these examples.
< 실시예 1 > 씨엘에이(CLA) 생성 유산균의 선발Example 1 Selection of CLA-producing Lactic Acid Bacteria
유산균은 고려대학교 응용동물과학과, 오클라호마 주립 대학 축산학과(미합중국), 코넬대학교 식품공학과(미합중국), 그리고 주식회사 컬쳐시스템(Culture system; 미합중국)에서 사람의 분변에서 채취하여 냉동 보관중인 유산균을 분양 받아 사용하였다.Lactobacillus was collected from human feces from the Department of Applied Animal Science, Korea University, Oklahoma State University, Livestock (US), Cornell University (US), and Culture System (United States). .
본 실험에 사용한 유산균은 2 중량% 트립톤, 효모추출물 0.7 중량% 그리고 포도당 2 중량%를 함유한 배지에서 혐기적으로 37℃의 항온기에서 배양하였다. 11중량% 환원 탈유유로 제조된 배지에 멸균된 리놀렌인산 100 밀리그램 당 리터 의함량으로 첨가한 후 37℃ 항온수조에서 배양하였다.The lactic acid bacteria used in this experiment were incubated anaerobically at 37 ° C. in a medium containing 2 wt% tryptone, 0.7 wt% yeast extract and 2 wt% glucose. To a medium prepared with 11% by weight reduced deoiled milk was added at a content of liter per 100 milligrams of sterile linoleic phosphate, and then cultured in a 37 ° C. constant temperature water bath.
상기 배양액을 이소프로파놀과 핵산을 3:2로 혼합된 혼합액에 잘 흔들어서 추출한 다음 원심분리 한 후 상등 액을 취해 2% 황산을 촉매로 이용, 메칠 알코올과 톨루엔 (1:1) 혼합액에서 70℃ 에서 30분간 유도체화를 시킨 후 가스크로마토드래피를 이용하여 분석하여 그 결과를 표 1에 나타내었다.The culture solution was extracted by shaking well with a mixture of isopropanol and nucleic acid in a 3: 2 mixture, followed by centrifugation, taking a supernatant, and using 2% sulfuric acid as a catalyst. 70 ℃ in a mixture of methyl alcohol and toluene (1: 1). After derivatization for 30 minutes at and analyzed using gas chromatographies, the results are shown in Table 1.
- : 생산하지 않음-: Do not produce
+ : 지질 그램당 3밀리그램 이하 생산+: Less than 3 milligrams per gram of lipid
++ : 지질 그램당 3밀리그램 이상, 5밀리그램 이하 생산++: Produces more than 3 and less than 5 milligrams per gram of lipid
+++ : 지질 그램당 5밀리그램 이상 생산+++: Produce more than 5 milligrams per gram of lipid
상기 표 1에서 보여주는 바와 같이, 씨엘에이(CLA) 생산능에 있어 비피도박테리아 롱검이 다른 종류의 유산균보다 우수하게 나타났으며, 락토바실러스 카제이균과 락토바실러스 애시도 필러스 균도 씨엘에이(CLA)를 다소 생산하는 것으로 나타났다.As shown in Table 1, Bifidobacteria long gum was superior to other types of lactic acid bacteria in the production capacity of CLA, and Lactobacillus casei and Lactobacillus ashdophyllus bacteria were also CLA (CLA). It appeared to produce somewhat.
< 실시예 2 > 씨엘에이(CLA) 함유 발효유의 제조<Example 2> Preparation of fermented milk containing CLA
무지 유고형분을 5∼20 중량%로 조정한 원료유에 해바라기씨 기름 또는 옥수수 기름을 0.02∼5 중량%가 되도록 첨가하여 균질화 한 다음, 선발된 유산균을 스타아터로 만들어 첨가한 후 30∼45℃의 온도에서 배양하여 배양액을 제조하였다.After homogenizing by adding 0.02 to 5% by weight of sunflower seed oil or corn oil to the raw oil adjusted to 5 to 20% by weight of solid milk solids, the selected lactic acid bacteria were added to make a starter and then added at 30 to 45 ° C. Cultures were prepared by incubation at temperature.
이렇게 제조된 발효원액에 기호성을 증진시키기 위하여 여기에 정제수, 각종 과즙, 당류 들을 표 2에서 제시한 바와 같이 혼합하여 표 3에서와 같이, 관능특성을 포함한 이화학적 특성을 조사하였다.In order to enhance palatability in the fermentation broth thus prepared, purified water, various juices, and sugars were mixed as shown in Table 2, and as shown in Table 3, physicochemical characteristics including sensory properties were investigated.
1)씨엘에이 함량은 지질 그램당 밀리그램을 의미함 1) CC content means milligrams per gram of lipid
2)기호성 : 9 (아주 좋다) ∼ 1 (아주 싫다) 2) Palatability: 9 (very good) to 1 (very much)
3)신 맛 : 9 (아주 강하다) ∼ 1 (아주 약하다) 3) Sour taste: 9 (very strong) to 1 (very weak)
4)비교예 1 : 시판 농후 발효유 (무지유고형분 8% 이상) 4) Comparative Example 1: Commercially enriched fermented milk (more than 8% solid milk solids)
5)비교예 2 : 시판 액상 발효유 (무지유고형분 8% 이하) 5) Comparative Example 2: Commercial liquid fermented milk (non-fat solid content of 8% or less)
상기 표 3에서 보여주는 바와 같이, 본 발명의 씨엘에이를 함유 발효유는 무지유 고형분 8% 인 경우 기존의 농후 발효유 보다 씨엘에이를 3배이상 함유하는 것으로 확인되었으며, 무지유 고형분이 4%인 경우에는 기존의 액상발효유 보다 약 6배 이상 함유하였다. 또한 pH나 기호성에서 기존 제품과 별 차이가 없이 우수하게 나타났다.As shown in Table 3, the fermented milk containing the CL of the present invention was confirmed to contain more than three times the SL of the conventional rich fermented milk when the non-fat solid content of 8%, the non-fat solid content of 4% It contained about 6 times more than conventional liquid fermented milk. In addition, pH or palatability was excellent without any difference from existing products.
< 실시예 3 > 동물실험을 통한 항암효과 비교Example 3 Comparison of Anticancer Effects through Animal Experiments
6주령 무균 자성 마우스를 중국 암연구소에서 구입하여 케이지당 5마리씩으로 하여 예비 사육한 다음 사용하였는데, 이때 사육실은 각각 12시간씩 점등을 조절하였으며 물과 조제사료는 자유섭취 하도록 하였다.Six-week-old sterile magnetic mice were purchased from the Chinese Cancer Research Institute, and were used after preliminary breeding with 5 birds per cage. At this time, the breeding room was controlled for 12 hours each, and the water and the feed were freely ingested.
무지 유고형분을 5-20 중량%로 조정한 원료유에 해바라기씨 기름을 10∼1000 중량부가 되도록 첨가하여 균질화 한 다음 씨엘에이(CLA)를 생산하는 유산균의 하나인 비피도박테리움 롱검을 배양시킨 배양액 또는 배양 후 균체를 건조시킨 분말을 접종하여 30-45℃ 온도로 배양시킨 다음 pH가 4.7∼4.2가 되면 배양을 종료하여 발효유를 제조하였으며 제조된 발효유를 이용하여 동물실험에 사용하였다. 발암물질인 벤조피렌(Benzopyrene)을 이용하여 전위(前胃)암을 유발시킨 후 각각의 제조된 요구르트를 물로 2배 희석하여 4주 동안 자유로이 섭취하도록 하였고, 대조군 1은 물과 조제 사료만 섭취하도록 하였고, 대조군 2는 일반 발효유를, 대조구 3은 해바라기씨 오일을 동일한 방법으로 섭취하도록 하였다.Cultured cultured Bifidobacterium longgum, one of the lactic acid bacteria producing CLA, by homogenizing by adding 10 ~ 1000 parts by weight of sunflower seed oil to raw oil adjusted to 5-20% by weight of solid milk solids. Alternatively, after incubation, the cells were inoculated with the dried powder and incubated at a temperature of 30-45 ° C., and when the pH reached 4.7˜4.2, the culture was terminated to prepare fermented milk, which was used in animal experiments using the prepared fermented milk. After inducing potential cancer by using benzopyrene, a carcinogen, each prepared yogurt was diluted twice with water for free intake for 4 weeks. , Control 2 was to consume normal fermented milk, control 3 was to consume sunflower seed oil in the same way.
표 4에서 제시된 바와 같이 발암율을 비교하여 보면, 씨엘에이 함유 발효유군은 53.3%로 대조군들에 비해서 매우 낮은 것으로 나타나 본 씨엘에이 함유 발효유의 투여는 전위암 생성을 효과적으로 억제시킴을 알 수 있었다.As shown in Table 4, when comparing the carcinogenicity rate, the fermented milk group containing the CLA was 53.3%, which is very low compared to the control group, and the administration of the CLA-containing fermented milk effectively inhibited the generation of dislocation cancer.
* 유의적 차이가 인정되었음 (P<0.01)* Significant difference was recognized (P <0.01)
이상에서 상세히 살펴본 바와 같이, 본 발명은 높은 항동맥 경화와 항암효과를 지닌 것으로 밝혀진 씨엘에이(CLA)를 생성하는 유산균을 선발하여 그 유산균을 발효유 제조에 이용함으로서, 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성이 보장되어 인체 건강에 유용하게 활용될 수 있는 효과와 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용할 수 있음으로서 산업발전에 유용한 효과가 있다.As described in detail above, the present invention is to select the lactic acid bacteria that produce CLA (CLA) that has been found to have a high anti-arteriosclerosis and anti-cancer effect and by using the lactic acid bacteria in fermented milk production, the formal effect of fermented milk and anti-cancer of CLA The effects are mutually organic to ensure improved functionality, and can be effectively used for human health, and can be suitably used for the preparation of suits, feed additives, and powdered lactic acid bacteria products, which are useful for industrial development.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0014858A KR100371549B1 (en) | 2000-03-23 | 2000-03-23 | Development of fermented dairy products containing CLA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0014858A KR100371549B1 (en) | 2000-03-23 | 2000-03-23 | Development of fermented dairy products containing CLA |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010089858A true KR20010089858A (en) | 2001-10-12 |
KR100371549B1 KR100371549B1 (en) | 2003-02-06 |
Family
ID=19657948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0014858A KR100371549B1 (en) | 2000-03-23 | 2000-03-23 | Development of fermented dairy products containing CLA |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100371549B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005001068A1 (en) * | 2003-06-28 | 2005-01-06 | Chil-Surk Yoon | A BIFIDOBACTERIUM BREVE LMC520 STRAIN CONTAINING A PLASMID Pbc520, A METHOD FOR PREPARATION OF CONJUGATED FATTY ACIDS AND FERMENTED MILKS CONTAINING SUCH FATTY ACIDS USING THE SAME STRAIN, AND USE OF A PLASMID pBC520 |
EP1500706A1 (en) * | 2002-04-12 | 2005-01-26 | Kabushiki Kaisha Yakult Honsha | Process for producing conjugated fatty acid and food/drink obtained by the process |
WO2008128767A3 (en) * | 2007-04-24 | 2008-12-11 | Lipid Nutrition Bv | Low sugar yoghurt |
KR101401530B1 (en) * | 2012-07-06 | 2014-06-11 | (주)케비젠 | Bifidobacterium longum strain producing conjugated linoleic acid and uses thereof |
KR101726416B1 (en) * | 2015-10-08 | 2017-04-14 | 재단법인 임실치즈앤식품연구소 | Fermented milk including Conjugated linoleic acid having Anti-diabetic effect and the manufacturing method thereof |
CN114958662A (en) * | 2022-05-13 | 2022-08-30 | 江南大学 | Bifidobacterium longum subspecies longum capable of relieving constipation and simultaneously up-regulating IL-10 to relieve inflammation and application thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004043824A1 (en) * | 2004-09-10 | 2006-03-16 | Cognis Ip Management Gmbh | Emulsions with unsaturated fatty acids and their esters |
KR100953915B1 (en) | 2007-12-20 | 2010-04-22 | 고려대학교 산학협력단 | A method for preparing a cheese having rich conjugated linoleic acid by controlling lactating time, feeding regimen and ripening |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856149A (en) * | 1995-06-01 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
-
2000
- 2000-03-23 KR KR10-2000-0014858A patent/KR100371549B1/en not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1500706A1 (en) * | 2002-04-12 | 2005-01-26 | Kabushiki Kaisha Yakult Honsha | Process for producing conjugated fatty acid and food/drink obtained by the process |
EP1500706A4 (en) * | 2002-04-12 | 2005-08-03 | Yakult Honsha Kk | Process for producing conjugated fatty acid and food/drink obtained by the process |
WO2005001068A1 (en) * | 2003-06-28 | 2005-01-06 | Chil-Surk Yoon | A BIFIDOBACTERIUM BREVE LMC520 STRAIN CONTAINING A PLASMID Pbc520, A METHOD FOR PREPARATION OF CONJUGATED FATTY ACIDS AND FERMENTED MILKS CONTAINING SUCH FATTY ACIDS USING THE SAME STRAIN, AND USE OF A PLASMID pBC520 |
WO2008128767A3 (en) * | 2007-04-24 | 2008-12-11 | Lipid Nutrition Bv | Low sugar yoghurt |
KR101401530B1 (en) * | 2012-07-06 | 2014-06-11 | (주)케비젠 | Bifidobacterium longum strain producing conjugated linoleic acid and uses thereof |
KR101726416B1 (en) * | 2015-10-08 | 2017-04-14 | 재단법인 임실치즈앤식품연구소 | Fermented milk including Conjugated linoleic acid having Anti-diabetic effect and the manufacturing method thereof |
CN114958662A (en) * | 2022-05-13 | 2022-08-30 | 江南大学 | Bifidobacterium longum subspecies longum capable of relieving constipation and simultaneously up-regulating IL-10 to relieve inflammation and application thereof |
CN114958662B (en) * | 2022-05-13 | 2023-10-03 | 江南大学 | Bifidobacterium longum subspecies capable of relieving constipation and up-regulating IL-10 to relieve inflammation and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100371549B1 (en) | 2003-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Beheshtipour et al. | Supplementation of Spirulina platensis and Chlorella vulgaris algae into probiotic fermented milks | |
JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
US5516684A (en) | Biologically pure culture of Lactobacillus acidophilus FERM-P-14204 or FERM-P-14205 | |
JPH05252934A (en) | Probiotic | |
JP5247012B2 (en) | Fatty liver suppressant | |
US8765118B2 (en) | Lactococcus lactis strain with high vitamin K2 production | |
US11484583B2 (en) | Intestinal bacteria Butyribacter intestini and application thereof | |
JP2009542204A (en) | Functional lactic acid bacteria fermentation composition excellent in diet effect | |
JP6894097B2 (en) | Composition for improving renal anemia | |
US8673616B2 (en) | Lactococcus lactis strain with high vitamin K2 production | |
JPWO2018003900A1 (en) | Composition for use in improving nutritional status | |
JP5847587B2 (en) | Propionic acid bacterium-containing composition and method of using the same | |
KR100371549B1 (en) | Development of fermented dairy products containing CLA | |
JP2018083761A (en) | Agent for inhibiting decomposition of muscle | |
CN110982731A (en) | Space-induced lactobacillus plantarum ST20-71 with probiotic characteristics and application thereof | |
EP0587657A1 (en) | Food additive for human and animal foodstuffs and foodstuffs containing same | |
EP3479836A1 (en) | Cartilage regeneration facilitating composition | |
DK2419506T3 (en) | BAKERY STUMS WITH AN EXCELLENT ABILITY TO MAKE MENAQUINON | |
JP2002058425A (en) | Fermented food containing conjugated fatty acid and method for producing the same | |
KR100417390B1 (en) | Novel Microorganism of Bifidobacterium breve LMC7 Bifidus strain, Method for Production of Conjugated Fatty Acid and Fermented Milk using Said Microorganism | |
Jena et al. | Bifidobacteria in Fermented Dairy Foods: A Health Beneficial Outlook | |
JP5077157B2 (en) | Functional food and drink | |
RU2802189C1 (en) | Strain of bifidobacterium animalis subsp. lactis used to produce fermented and non-fermented food products and biologically active food supplements (options) | |
US20230285474A1 (en) | Novel bifidobacterium breve idcc 4401 strain and its dead cell id-bbr4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia | |
Sharma et al. | AN OVERVIEW: PROBIOTIC MICROBES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080124 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |